ALTER Stock Overview
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Theradiag SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.26 |
| 52 Week High | €2.39 |
| 52 Week Low | €1.18 |
| Beta | -0.27 |
| 1 Month Change | -5.97% |
| 3 Month Change | -43.75% |
| 1 Year Change | -44.86% |
| 3 Year Change | -51.91% |
| 5 Year Change | 35.78% |
| Change since IPO | -77.74% |
Recent News & Updates
Slammed 26% Theradiag SA (EPA:ALTER) Screens Well Here But There Might Be A Catch
Oct 04
Theradiag (EPA:ALTER) Might Have The Makings Of A Multi-Bagger
Oct 03Shareholder Returns
| ALTER | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -4.9% | -1.7% | -1.3% |
| 1Y | -44.9% | 16.8% | 5.2% |
Return vs Industry: ALTER underperformed the French Medical Equipment industry which returned 5.2% over the past year.
Return vs Market: ALTER underperformed the French Market which returned 12.7% over the past year.
Price Volatility
| ALTER volatility | |
|---|---|
| ALTER Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALTER's share price has been volatile over the past 3 months.
Volatility Over Time: ALTER's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 61 | Simon Daviere | www.theradiag.com |
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer.
Theradiag SA Fundamentals Summary
| ALTER fundamental statistics | |
|---|---|
| Market cap | €16.44m |
| Earnings (TTM) | €421.92k |
| Revenue (TTM) | €13.51m |
39.0x
P/E Ratio1.2x
P/S RatioIs ALTER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTER income statement (TTM) | |
|---|---|
| Revenue | €13.51m |
| Cost of Revenue | €7.24m |
| Gross Profit | €6.26m |
| Other Expenses | €5.84m |
| Earnings | €421.92k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 46.37% |
| Net Profit Margin | 3.12% |
| Debt/Equity Ratio | 17.1% |
How did ALTER perform over the long term?
See historical performance and comparison